Viferon-4 candles 3000000me №10

Mechanism of action

Viferon is a human recombinant Interferon alfa-2b drug.
It has antiviral, immunomodulatory and antiproliferative effects. Under the influence of interferon in the body, the activity of natural killer cells, T-helper cells, cytotoxic T-lymphocytes, phagocytic activity, B-lymphocyte differentiation intensity, and expression of MHC type I and II antigens increase.
The drug also directly inhibits the replication and transcription of viruses, chlamydia.
Damage to cell membranes, observed during the development of an infectious process, is the cause of a decrease in the antiviral activity of interferon. Tocopherol acetate and Ascorbic acid, which are part of the drug Viferon, are membrane-stabilizing components, antioxidants, in combination with which the antiviral activity of recombinant interferon alpha-2b increases 10-14 times. In addition, the immunomodulatory effect of interferon on T- and B-lymphocytes is enhanced, the content of immunoglobulin E is normalized, there are no side effects (fever, fever, influenza-like phenomena) arising from the parenteral administration of interferon preparations.
It has been established that when using Viferon for 2 years, antibodies that neutralize the antiviral activity of recombinant interferon alpha-2b are not formed.
The use of the drug Viferon can significantly reduce the course dose and the duration of courses of treatment with antibiotics, hormones and cytotoxic drugs.
Features of the introduction of the dosage form provide long-term circulation in the blood of interferon alfa-2b.

12 h after rectal administration of Viferon, a decrease in the level of interferon in the blood serum is observed, which necessitates its repeated administration.

Indications and usage

- in the treatment of various infectious and inflammatory diseases in children, including newborns and premature infants: acute respiratory viral infections, including influenza, including those complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial), meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis);

- in the complex therapy of chronic viral hepatitis B, C, D in children and adults, including in combination with the use of plasmapheresis and hemosorption, with chronic viral hepatitis of marked activity, including those complicated by liver cirrhosis;

- in complex therapy in adults, including pregnant women, with urogenital infection (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellosis, human papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis), primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild to moderate course, including urogenital form;

- in the treatment of acute respiratory viral infections, including influenza, including those complicated by bacterial infection in adults.

Dosage and administration

Viferon suppositories are administered rectally.

newborns, including premature babies with gestational age of more than 34 weeks, are prescribed Viferon 150000 IU daily 1 suppository 2 times a day after 12 hours. The course of treatment is 5 days.

Premature newborns with gestational age of less than 34 weeks are prescribed Viferon 150000 IU daily, 1 suppository 3 times a day after 8 hours. The course of treatment is 5 days.
The recommended number of courses for various infectious and inflammatory diseases in children, including newborns and premature infants: SARS, including influenza, including those complicated by a bacterial infection, 1-2 courses; pneumonia (bacterial, viral, chlamydia) - 1-2 courses, sepsis - 2-3 courses, meningitis - 1-2 courses, herpes infection - 2 courses, enterovirus infection 1-2 courses, cytomegalovirus infection - 2-3 courses, mycoplasmosis, candidiasis, including visceral, - 2-3 courses. The break between courses is 5 days. According to clinical indications, therapy can be continued.

: for children with chronic viral hepatitis, the drug is prescribed in the following age doses: up to 6 months, 300,000-500,000 IU per day; from 6 to 12 months - 500,000 IU per day. At the age from 1 year to 7 years - 3,000,000 IU per 1 m2 of body surface area per day. At the age of over 7 years - 5000000 IU per 1 m2 of body surface area per day. Calculation of the dose of the drug for each individual patient is made by multiplying the recommended dose for a given age by the surface area of ​​the body, calculated from the nomogram to calculate the surface area of ​​the body in height and weight according to Harford, Terry and Rourke, divided into 2 injections, rounded to the dosage of the appropriate suppository. The drug is used 2 times a day after 12 hours for the first 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Children with chronic viral hepatitis expressed activity and liver cirrhosis before plasmapheresis and / or hemosorption indicated the use of the drug for 14 days daily 1 suppository 2 times a day after 12 hours (children under 7 years old Viferon 150000 IU, children over 7 years old - Viferon 500,000 IU).

Adults with chronic viral hepatitis are prescribed Viferon 3000000 IU, 1 suppository 2 times a day after 12 hours for 10 days daily, then three times a week every other day for 6-12 months. The duration of treatment is determined by clinical efficacy and laboratory parameters.

Adults, with the above infections, except for herpetic, prescribe Viferon 500000 IU and 1 suppository 2 times a day after 12 hours. The course is 5-10 days. According to clinical indications, therapy can be continued with breaks between courses of 5 days.

Viferon is prescribed 1000000 IU in 1 suppository 2 times a day after 12 hours. The course of treatment is 10 days or more for a recurrent infection. It is recommended to start treatment immediately when the first signs of lesions of the skin and mucous membranes (itching, burning, redness) appear. In the treatment of recurrent herpes, it is desirable to begin treatment in the prodromal period or at the very beginning of the manifestation of signs of relapse.

In pregnant women with urogenital infections, including herpetic, in the second trimester of pregnancy (starting from week 14) - Viferon 500,000 IU in 1 suppository after 12 hours (2 times a day) for 10 days, then in 1 suppository in 12 hours ( 2 times a day) twice a week - 10 days.Then, after 4 weeks, preventive courses of the drug Viferon 150000 IU are held on 1 suppository every 12 hours - for 5 days, the prophylactic course is repeated every 4 weeks. If necessary, it is possible to conduct a therapeutic course before giving birth.

Apply Viferon 500000 IU to 1 suppository, 2 times a day every 12 h. The course of treatment is 5-10 days.

In rare cases, allergic reactions may develop (skin rash, itching)

Hypersensitivity to the components of the drug.

Viferon is approved for use from the 14th week of pregnancy. There are no restrictions for use during lactation.

For the treatment of a wide range of infectious and inflammatory diseases, Viferon can be used in combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.
There is evidence of the effectiveness of the drug Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpes infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old; viral hepatitis in adults, acute respiratory viral infections, influenza, bronchial asthma, juvenile rheumatoid arthritis; meningeal form of tick-borne encephalitis; prostatitis of various etiologies; purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephritis.

The drug should be stored in a dry, dark place at a temperature of from 2 ° to 8 ° C.